{"id":"W4296468589","doi":"10.1016/s2152-2650(22)01538-5","title":"ABCL-412 Clinical Activity of CC-99282, a Novel, Oral, Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) –Results From CC-99282-NHL-001 (NCT03930953) a First-in-Human, Phase 1, Open-Label, Multicenter Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Lenalidomide; Internal medicine; Adverse effect; Lymphoma; Follicular lymphoma; Gastroenterology; Refractory (planetary science); Cereblon; Bendamustine; Oncology; Chemotherapy; Rituximab; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005734198,0.0006456687,0.0008279514,0.0002521302,0.0001939568,0.0006539243,0.000460636,0.0006904753,0.00341426],"category_scores_gemma":[0.0003482967,0.0002570777,0.0006878862,0.0002685596,0.0003720367,0.0004530453,0.0001666417,0.001674214,0.0009119157],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006993892,"about_ca_system_score_gemma":0.0007341239,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001180397,"about_ca_topic_score_gemma":0.003577444,"domain_scores_codex":[0.9998137,0.00007372176,0.000009870534,0.00002657623,0.00002774127,0.000048367],"domain_scores_gemma":[0.9997873,0.00003215909,0.00004640219,0.00001843083,0.00001716526,0.00009866382],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3933601,0.02842015,0.01439643,0.001489121,0.002651202,0.0007221235,0.0003215694,0.006303275,0.2158973,0.001028965,0.01776337,0.3176464],"study_design_scores_gemma":[0.415714,0.4243999,0.07637376,0.0001693352,0.002088167,0.001944982,0.0002778079,0.005878314,0.03902656,0.0008061851,0.03320227,0.0001187583],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9887527,0.003516689,0.0004274591,0.0005214821,0.00007631253,0.0004921353,0.001622071,0.0001679235,0.004423293],"genre_scores_gemma":[0.9882171,0.002064084,0.0006284269,0.0005508783,0.00007405879,0.0002917771,0.004210268,0.00003550802,0.003927865],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00341426,"threshold_uncertainty_score":0.01142186,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04331036471946438,"score_gpt":0.3359455676268516,"score_spread":0.2926352029073872,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}